CEO & co-founder of Nuage Therapeutics, a Barcelona based spin off from the Institute of Biomedical Research (IRB) that exploits chemical biology and biomolecular condensation to develop potent and selective therapeutic agents targeting proteins with disordered regions for challenging indications to improve patient’s life.

Previously, CEO of CataloniaBio & HealthTech until the end of 2021, the organization that represents companies in the biomedicine and health sector in Catalonia comprising almost 200 member companies and knowledge stakeholders that are leaders in research, development (R&D) and innovation. Anido joins the board of CataloniaBio & HealthTech in 2018 and was the first woman president of the institution. She was also co-founder of Mosaic Biomedicals, a biotech company spin off from VHIO (Vall d’Hebron Institute of Oncology) based in Barcelona and dedicated to the development of innovative drugs for cancer treatment. She led the growth of Mosaic as CEO from 2012 until its merger with the Canadian company Northern Biologics in 2016, when she assumed the general direction of Mosaic and became Vice-President of Operations and Corporate Affairs at Northern. In 2020 the assets of the companies were successfully acquired by Boehringer Ingelheim and AstraZeneca.

PhD in Biology from the University of Barcelona and an MBA from Duke University (United States) with Certification in Health Sector Management and specialization in Entrepreneurship and Innovation. Anido accumulates over 10 years experience in cancer research at VHIO and was Associate at the Pipeline and Portfolio Planning Team at Genentech (Roche Group) in San Francisco. She has been awarded with the Premi FemTalent 2018, promoted by the Barcelona City Council. She has also received competitive grants from the Spanish Association Against Cancer (AECC in Spanish), Rafael del Pino Foundation, Duke University and Caja Madrid Foundation.